| |
| |
|
| Insider
Information: |
Gordon Carl L |
| Relationship: |
Director, 10% Owner |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
20 |
|
| Direct
Shares |
11,800 |
|
|
Indirect Shares
|
35,800,326 |
|
|
| Direct
Value |
$16,520 |
|
|
|
Indirect Value
|
$652,940,097 |
|
|
| Total
Shares |
35,812,126 |
|
|
| Total
Value |
$652,956,617 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
5
|
2
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
4
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
 -16.0%
|
-200.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Acadia Pharmaceuticals Inc |
ACAD |
Director |
2004-06-02 |
0 |
2005-04-20 |
1,395,612 |
Premium* |
|
|
Biocryst Pharmaceuticals Inc |
BCRX |
Director |
2005-12-02 |
0 |
2005-12-02 |
1,100,000 |
Premium* |
|
|
Pacira Pharmaceuticals, Inc. |
PCRX |
Director |
|
0 |
2011-02-08 |
2,828,941 |
Premium* |
|
|
Amarin Corp Plc |
AMRN |
Director |
2011-02-28 |
0 |
2012-09-04 |
5,700 |
Premium* |
|
|
Acceleron Pharma Inc |
XLRN |
Director |
|
0 |
2013-09-18 |
8,006 |
Premium* |
|
|
Intellia Therapeutics, Inc. |
NTLA |
Director |
2016-05-11 |
0 |
2016-05-11 |
2,662,180 |
Premium* |
|
|
Cartesian Therapeutics, Inc |
RNAC |
Director, 10% Owner |
|
0 |
2016-06-27 |
1,825,415 |
Premium* |
|
|
X4 Pharmaceuticals Inc |
XFOR |
Director, 10% Owner |
2017-11-20 |
0 |
2017-11-20 |
1,868,966 |
Premium* |
|
|
Armo Biosciences Inc |
ARMO |
Director |
2018-01-30 |
0 |
2018-06-22 |
0 |
Premium* |
|
|
Alector, Inc. |
ALEC |
Director, 10% Owner |
2019-02-11 |
0 |
2019-02-11 |
203,200 |
Premium* |
|
|
Turning Point Therapeutics, Inc. |
TPTX |
Director |
2019-04-22 |
0 |
2019-04-22 |
2,027,550 |
Premium* |
|
|
Prevail Therapeutics Inc. |
PRVL |
Director, 10% Owner |
|
0 |
2021-01-22 |
0 |
Premium* |
|
|
Keros Therapeutics, Inc. |
KROS |
Director |
2020-04-13 |
0 |
2024-08-13 |
119,522 |
Premium* |
|
|
Oric Pharmaceuticals, Inc. |
ORIC |
Director |
2020-04-24 |
0 |
2021-03-30 |
2,212,571 |
Premium* |
|
|
Adicet Bio, Inc |
ACET |
|
2024-06-05 |
11,800 |
2024-06-05 |
11,447,140 |
Premium* |
|
|
Kinnate Biopharma Inc. |
KNTE |
Director, 10% Owner |
2020-12-07 |
0 |
2024-04-03 |
0 |
Premium* |
|
|
Terns Pharmaceuticals, Inc. |
TERN |
Director, 10% Owner |
2021-02-09 |
0 |
2024-07-16 |
755,635 |
Premium* |
|
|
Disc Medicine, Inc |
IRON |
Director, 10% Owner |
|
0 |
2021-02-05 |
5,826,224 |
Premium* |
|
|
Theseus Pharmaceuticals, Inc. |
THRX |
Director, 10% Owner |
2021-10-12 |
0 |
2024-02-14 |
0 |
Premium* |
|
|
Arrivent Biopharma, Inc. |
AVBP |
Director, 10% Owner |
2024-01-30 |
0 |
2024-01-30 |
1,513,664 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
104 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ORIC |
Oric Pharmaceuticals, Inc... |
Director |
– • – |
2021-03-12 |
4 |
AS |
$30.29 |
$2,741,881 |
I/I |
(90,521) |
2,616,645 |
0 |
- |
|
| ORIC |
Oric Pharmaceuticals, Inc... |
Director |
– • – |
2021-03-11 |
4 |
AS |
$33.04 |
$1,934,525 |
I/I |
(58,551) |
2,707,166 |
0 |
- |
|
| KROS |
Keros Therapeutics, Inc. |
Director |
– • – |
2024-08-13 |
4 |
S |
$44.01 |
$11,002,500 |
I/I |
(250,000) |
119,522 |
0 |
- |
|
| ARMO |
Armo Biosciences Inc |
Director |
– • – |
2018-06-22 |
4 |
D |
$50.00 |
$205,945,150 |
I/I |
(4,118,903) |
0 |
0 |
- |
|
104 Records found
|
|
Page 5 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
